Adamis initiates Phase I/IIa trial of APC-100

According to a media release from Adamis Pharmaceuticals, the company has started to enroll patients into a Phase I/IIa clinical trial of APC-100 in men with castration-resistant prostate cancer (CRPC). … READ MORE …

On the feasibility of a “universal” cancer vaccine (but first in prostate cancer)

As some readers may be aware, one of the great biologic discoveries of the late 20th Century was the association between the length of the telomere (a piece of repeating DNA at the tips of each chromosome) and the ability of an individual cell to divide and replicate. … READ MORE …